Go Pro

Silvan Turkcan Analyst Performance

Analyst at Citizens Jmp

Silvan Turkcan is a stock analyst at Citizens Jmp focused in the medical sector, covering 11 publicly traded companies. Over the past year, Silvan Turkcan has issued 18 stock ratings, including buy and hold recommendations. While full access to Silvan Turkcan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Silvan Turkcan's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
18 Last 0 Years
Buy Recommendations
94.44% 17 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy94.4%17 ratings
Hold5.6%1 ratings
Sell0.0%0 ratings

Out of 18 total stock ratings issued by Silvan Turkcan at Citizens Jmp, the majority (94.4%) have been Buy recommendations, followed by 5.6% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
11 companies

Silvan Turkcan, an analyst at Citizens Jmp, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
90.9%
Computer and Technology
1 company
9.1%

Silvan Turkcan of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
72.7%
COMM INFRASTRUCTURE
1 company
9.1%
MED - GENERIC DRG
1 company
9.1%
MED - DRUGS
1 company
9.1%

Silvan Turkcan's Ratings History at Citizens Jmp

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
7/20/2026Initiated Coverage$25.87$51.00Outperform
Bandwidth Inc. stock logo
BAND
Bandwidth
7/20/2026Boost Price Target$73.74$86.00Market Outperform
Celcuity, Inc. stock logo
CELC
Celcuity
7/15/2026Boost Price Target$92.61$177.00Market Outperform
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
7/6/2026Reiterated Rating$60.08$80.00Market Outperform
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
7/2/2026Reiterated Rating$6.65$11.00Market Outperform
Exelixis, Inc. stock logo
EXEL
Exelixis
6/24/2026Boost Price Target$51.34$55.00Market Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
6/15/2026Reiterated Rating$13.39$30.00Market Outperform
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5/20/2026Boost Price Target$12.07$21.00Market Outperform
enGene Holdings Inc. stock logo
ENGN
enGene
5/8/2026Downgrade$1.72Market Perform
Celcuity, Inc. stock logo
CELC
Celcuity
5/4/2026Boost Price Target$146.64$160.00Market Outperform
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4/28/2026Boost Price Target$13.52$19.00Market Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4/28/2026Boost Price Target$13.64$30.00Market Outperform
Celcuity, Inc. stock logo
CELC
Celcuity
4/27/2026Initiated Coverage$121.03$150.00Market Outperform
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
4/27/2026Initiated Coverage$2.35$9.00Market Outperform
Cellectis S.A. stock logo
CLLS
Cellectis
4/14/2026Reiterated Rating$4.28$8.00Market Outperform
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
3/17/2026Boost Price Target$10.01$17.00Market Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3/3/2026Boost Price Target$15.44$28.00Market Outperform
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
1/30/2026Lower Price Target$53.35$80.00Market Outperform